Table 5.
Treatment success rates (cure + improvement) in patients with multiresistant pathogens by drug-resistance phenotype (patients with evaluable treatment outcome; n = 215)
| Treatment success % (n/N) | Patients with documented MRB infection | |||
|---|---|---|---|---|
| Any MRB | VRE | MRSA | ESBL | |
| Total MRB population | 91.6 % (197/215) | 97.6 % (41/42) | 90.2 % (120/132) | 91.0 % (61/67) |
| Intraabdominal infection (cIAI) | 91.4 % (64/70) | 96.3 % (26/27) | 89.5 % (17/19) | 91.4 % (32/35) |
| Skin and soft tissue infection (cSSTI) | 94.5 % (52/55) | 100 % (3/3) | 94.0 % (47/50) | 100 % (4/4) |
| Diabetic foot infection (DFI) | 83.3 % (25/30) | −(0/0) | 83.3 % (25/30) | 66.6 % (2/3) |
| Community-acquired pneumonia (CAP) | 100 % (13/13) | 100 % (1/1) | 100 % (11/11) | 100 % (5/5) |
| Hospital-acquired pneumonia (HAP) | 86.7 % (26/30) | −(0/0) | 85.7 % (18/21) | 88.8 % (8/9) |
| Blood stream infection (BSI) | 100 % (22/22) | 100 % (4/4) | 100 % (15/15) | 100 % (8/8) |
| Multiple-site infection (MSI) | 81.5 % (22/27) | 100 % (4/4) | 76.5 % (13/17) | 83.3 % (10/12) |
Patients could have more than one MRB